Blog

How (Not) to Speak Australian

How (Not) to Speak Australian

G’day, mate. In case you didn’t know, that’s Australian for good day, friend. However, to our untrained ears, as Americans, it sounds like, “good eye might.” More like “good ear might” since we’re talking about Australian accents. In the 1980s, Foster’s drink company...

read more
FORTRESS TUMOR: RRx-001 and AdAPT-001

FORTRESS TUMOR: RRx-001 and AdAPT-001

  The maxim that “a man’s home is his castle” is made literal by tumors, which firmly entrench themselves behind castle-like barriers as a defense against the attritional war waged against them by chemotherapy, radiation, and immunotherapy. These barriers are...

read more
The Debate About Daylight Saving Time Is A Snoozzze

The Debate About Daylight Saving Time Is A Snoozzze

On Sunday, March 12 at 2 a.m., don’t forget to advance your clocks forward one hour for Daylight Saving Time (DST). (Remember spring forward, fall back). This applies to most of the country, Hawaii, Arizona, Puerto Rico, Guam, and the U.S. Virgin Islands excepted....

read more
All Killer, No Filler (AKNF)

All Killer, No Filler (AKNF)

In a TV review about a serial killer, we came across this pithy phrase: “all killer, no filler” (AKNF). AKNF denotes no extraneous content i.e., no filler, which perfectly encapsulates the minimalist design and effectiveness of the oncolytic adenovirus, AdAPT-001....

read more
EpicentRx Explains: What is Anergy?

EpicentRx Explains: What is Anergy?

“Anergy” is a commonly used term in immuno-oncology, particularly in conjunction with T cells. So, what exactly does it mean and in what context is it used? The dictionary defines it as the “absence of the normal immune response to a particular antigen or allergen.” A...

read more
EpicentRx presents at GI ASCO 2023

EpicentRx presents at GI ASCO 2023

“It’s like Avastin on steroids!” This direct quote came courtesy of an executive at a major pharmaceutical company after he reviewed the mechanism of action of RRx-001 and learned about the results of a Phase 2 randomized trial called ROCKET of RRx-001 vs. regorafenib...

read more
How Did EpicentRx Become EpicentRx?

How Did EpicentRx Become EpicentRx?

¡Más que una Radio! The names of companies, especially biotech companies, are often non-intuitive, hard to pronounce and even harder to spell, sometimes on purpose, making it next to impossible to figure out the general focus of these companies let alone exactly what...

read more
A Look Back at 2022 as We Look Forward to 2023

A Look Back at 2022 as We Look Forward to 2023

To readers of this blog, whoever you are, and however few or many you may be, Happy January 2023. January is named after Janus, the Roman God of beginnings and endings, usually depicted with two faces: one looking forward into the future and one looking backward at...

read more
EpicentRx at the 4th Annual Inflammasome Therapeutics Summit

EpicentRx at the 4th Annual Inflammasome Therapeutics Summit

Interested in a wicked good analogy? Well look no further than the 30-minute presentation given by Drs. Bryan Oronsky and Richard Gordon at the 2022 Inflammasome Therapeutics Summit in Boston, Massachusetts. In the presentation, Dr. Oronsky compared inflammation to...

read more
Q&A on the Recent Spike of Respiratory Viruses

Q&A on the Recent Spike of Respiratory Viruses

Just when we thought it was safe to go back in the water, and as if we didn’t have enough scary words to contend with, a new one making the rounds is “tripledemic”, involving simultaneous infection with COVID, the flu, and RSV. Yikes…more viral spikes! The proverb...

read more
AdAPT-001 Does It Beta

AdAPT-001 Does It Beta

What do U.S. fraternities and sororities, the Bible, COVID-19 (e.g., the alpha, delta, omicron variants) and EpicentRx’s AdAPT-001 oncolytic adenovirus have in common? Answer: Ancient Greek letters. EpicentRx’s AdAPT-001 oncolytic adenovirus carries a “TGF-beta trap.”...

read more
At EpicentRx we follow the data — not the crowd

At EpicentRx we follow the data — not the crowd

Two famous quotes attributed to the Great One, ice hockey legend Wayne Gretzky, “I skate to where the puck is going, not where it has been,” and “you miss 100% of the shots you never take,” perfectly encapsulate the corporate strategy at EpicentRx.

read more
Don’t Forget about Inflammation in AD

Don’t Forget about Inflammation in AD

EpicentRx presents data poster at Alzheimer’s Association International Conference (AAIC) Alzheimer’s Disease (AD), the leading worldwide cause of dementia or cognitive decline, continues (and will continue) to perplex the medical community until its main causes are...

read more
Spotlight on the Adenovirus of AdAPT-001

Spotlight on the Adenovirus of AdAPT-001

Fun fact: “Adenovirus,” a DNA virus, that has been used as a delivery vehicle for spike-based COVID vaccines, is named from the human adenoids, a tonsil-like organ in the back of the nose, where it was first isolated. The purpose of the adenoids is to fight...

read more
ASCO and EpicentRx on the Go

ASCO and EpicentRx on the Go

In June, EpicentRx was truly “on the go,” arriving at ASCO in Chicago directly from Scottsdale, Arizona where the company just one day prior presented data on the lipid-lowering effects of its small molecule, RRx-001, at the National Lipid Association (NLA), hence...

read more